NIH VideoCast - Immune checkpoint blockade in cancer therapy: historical perspective, new opportunities, and prospects for cures

Skip Navigation

Immune checkpoint blockade in cancer therapy: historical perspective, new opportunities, and prospects for cures

Loading... Loading video...

2,175 Views

Air date:	Wednesday, March 11, 2020, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 2,175 (822 Live, 1,353 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:03:23
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director’s Wednesday Afternoon Lecture Series James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." Among Allison's most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-DeBakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.

NLM Title:	Immune checkpoint blockade in cancer therapy : historical perspective, new opportunities, and prospects for cures / James P. Allison.
Author:	Allison, James P. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Director's Wednesday Afternoon Lecture Series James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, for their discovery of cancer therapy by inhibition of negative immune regulation. Among Allison's most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naive T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-DeBakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
Subjects:	CD28 Antigens--therapeutic use CTLA-4 Antigen--therapeutic use Immunotherapy--methods Neoplasms--therapy T-Lymphocytes--physiology
Publication Types:	Lecture Webcast

NLM Classification:	QZ 266
NLM ID:	101765816
CIT Live ID:	36081
Permanent link:	https://videocast.nih.gov/watch=36081

Related Videos...